Profound Medical Corp. (PROF)
4.78
0.06 (1.27%)
At close: Apr 17, 2025, 3:59 PM
4.45
-6.90%
Pre-market: Apr 21, 2025, 08:47 AM EDT
1.27% (1D)
| Bid | 4 |
| Market Cap | 143.54M |
| Revenue (ttm) | 6.98M |
| Net Income (ttm) | -22.48M |
| EPS (ttm) | -1.12 |
| PE Ratio (ttm) | -4.27 |
| Forward PE | -3.64 |
| Analyst | Strong Buy |
| Ask | 4.82 |
| Volume | 31,184 |
| Avg. Volume (20D) | 81,720 |
| Open | 4.75 |
| Previous Close | 4.72 |
| Day's Range | 4.62 - 4.88 |
| 52-Week Range | 3.90 - 11.42 |
| Beta | 0.62 |
About PROF
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sona...
Industry Medical - Devices
Sector Healthcare
IPO Date Oct 29, 2019
Employees 142
Stock Exchange NASDAQ
Ticker Symbol PROF
Website https://www.profoundmedical.com
Analyst Forecast
According to 1 analyst ratings, the average rating for PROF stock is "Strong Buy." The 12-month stock price forecast is $12, which is an increase of 151.05% from the latest price.
Stock ForecastsNext Earnings Release
Profound Medical Corp. is scheduled to release its earnings on May 8, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
9 months ago
+6.01%
Profound Medical shares are trading higher after S...
Unlock content with
Pro Subscription
